Frontiers in Microbiology (May 2017)
Helicobacter pylori Antibody Reactivities and Colorectal Cancer Risk in a Case-control Study in Spain
- Nerea Fernández de Larrea-Baz,
- Nerea Fernández de Larrea-Baz,
- Angelika Michel,
- Beatriz Romero,
- Beatriz Pérez-Gómez,
- Beatriz Pérez-Gómez,
- Beatriz Pérez-Gómez,
- Victor Moreno,
- Victor Moreno,
- Victor Moreno,
- Victor Moreno,
- Vicente Martín,
- Vicente Martín,
- Vicente Martín,
- Trinidad Dierssen-Sotos,
- Trinidad Dierssen-Sotos,
- José J. Jiménez-Moleón,
- José J. Jiménez-Moleón,
- José J. Jiménez-Moleón,
- Jesús Castilla,
- Jesús Castilla,
- Adonina Tardón,
- Adonina Tardón,
- Irune Ruiz,
- Rosana Peiró,
- Rosana Peiró,
- Antonio Tejada,
- María D. Chirlaque,
- María D. Chirlaque,
- María D. Chirlaque,
- Julia A. Butt,
- Rocío Olmedo-Requena,
- Rocío Olmedo-Requena,
- Rocío Olmedo-Requena,
- Inés Gómez-Acebo,
- Inés Gómez-Acebo,
- Pedro Linares,
- Elena Boldo,
- Elena Boldo,
- Elena Boldo,
- Antoni Castells,
- Antoni Castells,
- Antoni Castells,
- Antoni Castells,
- Michael Pawlita,
- Gemma Castaño-Vinyals,
- Gemma Castaño-Vinyals,
- Gemma Castaño-Vinyals,
- Gemma Castaño-Vinyals,
- Manolis Kogevinas,
- Manolis Kogevinas,
- Manolis Kogevinas,
- Manolis Kogevinas,
- Silvia de Sanjosé,
- Silvia de Sanjosé,
- Marina Pollán,
- Marina Pollán,
- Marina Pollán,
- Rosa del Campo,
- Rosa del Campo,
- Tim Waterboer,
- Nuria Aragonés,
- Nuria Aragonés
Affiliations
- Nerea Fernández de Larrea-Baz
- Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Instituto de Salud Carlos IIIMadrid, Spain
- Nerea Fernández de Larrea-Baz
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Angelika Michel
- Division of Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ)Heidelberg, Germany
- Beatriz Romero
- Department of Microbiology, Ramón y Cajal University Hospital (IRYCIS)Madrid, Spain
- Beatriz Pérez-Gómez
- Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Instituto de Salud Carlos IIIMadrid, Spain
- Beatriz Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Beatriz Pérez-Gómez
- Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (Puerta de Hierro Health Research Institute)Madrid, Spain
- Victor Moreno
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Victor Moreno
- Cancer Prevention and Control Program, Catalan Institute of OncologyHospitalet de Llobregat, Spain
- Victor Moreno
- Department of Clinical Sciences, Faculty of Medicine, University of BarcelonaBarcelona, Spain
- Victor Moreno
- Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL)Hospitalet de Llobregat, Spain
- Vicente Martín
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Vicente Martín
- The Research Group in Gene – Environment and Health Interactions, University of LeónLeón, Spain
- Vicente Martín
- 0Area of Preventive Medicine and Public Health, Faculty of Health Sciences, Department of Biomedical Sciences, University of LeónLeón, Spain
- Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Trinidad Dierssen-Sotos
- 1Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria-IDIVALSantander, Spain
- José J. Jiménez-Moleón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- José J. Jiménez-Moleón
- 2Granada Health Research Institute (ibs.GRANADA) – Instituto de Investigación Biosanitaria de GranadaGranada, Spain
- José J. Jiménez-Moleón
- 3Department of Preventive Medicine and Public Health, University of GranadaGranada, Spain
- Jesús Castilla
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Jesús Castilla
- 4Instituto de Salud Pública de Navarra, IdiSNA-Navarra Institute for Health ResearchPamplona, Spain
- Adonina Tardón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Adonina Tardón
- 5Molecular Epidemiology of Cancer Unit, Oncology Institute, Department of Medicine, University of OviedoOviedo, Spain
- Irune Ruiz
- 6Department of Pathology, Donostia University HospitalDonostia, Spain
- Rosana Peiró
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Rosana Peiró
- 7Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO) – Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana FISABIO–Salud PúblicaValencia, Spain
- Antonio Tejada
- 8Coloproctology Unit, Department of General Surgery, Huelva University Hospital ComplexHuelva, Spain
- María D. Chirlaque
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- María D. Chirlaque
- 9Department of Epidemiology, Regional Health Council, IMIB-ArrixacaMurcia, Spain
- María D. Chirlaque
- 0Department of Health and Social Sciences, University of MurciaMurcia, Spain
- Julia A. Butt
- Division of Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ)Heidelberg, Germany
- Rocío Olmedo-Requena
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Rocío Olmedo-Requena
- 2Granada Health Research Institute (ibs.GRANADA) – Instituto de Investigación Biosanitaria de GranadaGranada, Spain
- Rocío Olmedo-Requena
- 3Department of Preventive Medicine and Public Health, University of GranadaGranada, Spain
- Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Inés Gómez-Acebo
- 1Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria-IDIVALSantander, Spain
- Pedro Linares
- 1Department of Gastroenterology and Hepatology, Complejo Asistencial Universitario de LeónLeón, Spain
- Elena Boldo
- Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Instituto de Salud Carlos IIIMadrid, Spain
- Elena Boldo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Elena Boldo
- Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (Puerta de Hierro Health Research Institute)Madrid, Spain
- Antoni Castells
- 2Gastroenterology Department, Hospital ClínicBarcelona, Spain
- Antoni Castells
- 3Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Barcelona, Spain
- Antoni Castells
- 4CIBER Liver and Digestive Diseases – CIBER Enfermedades Hepáticas y Digestivas (CIBEREHD)Madrid, Spain
- Antoni Castells
- 5Department of Gastroenterology, University of BarcelonaBarcelona, Spain
- Michael Pawlita
- Division of Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ)Heidelberg, Germany
- Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Gemma Castaño-Vinyals
- 6ISGlobal, Centre for Research in Environmental Epidemiology (CREAL)Barcelona, Spain
- Gemma Castaño-Vinyals
- 7Hospital del Mar Medical Research Institute (IMIM)Barcelona, Spain
- Gemma Castaño-Vinyals
- 8Department of Experimental and Health Sciences, Universitat Pompeu FabraBarcelona, Spain
- Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Manolis Kogevinas
- 6ISGlobal, Centre for Research in Environmental Epidemiology (CREAL)Barcelona, Spain
- Manolis Kogevinas
- 7Hospital del Mar Medical Research Institute (IMIM)Barcelona, Spain
- Manolis Kogevinas
- 8Department of Experimental and Health Sciences, Universitat Pompeu FabraBarcelona, Spain
- Silvia de Sanjosé
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Silvia de Sanjosé
- 9Cancer Epidemiology and Research Program, Catalan Institute of Oncology-IDIBELLHospitalet de Llobregat, Spain
- Marina Pollán
- Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Instituto de Salud Carlos IIIMadrid, Spain
- Marina Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- Marina Pollán
- Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (Puerta de Hierro Health Research Institute)Madrid, Spain
- Rosa del Campo
- Department of Microbiology, Ramón y Cajal University Hospital (IRYCIS)Madrid, Spain
- Rosa del Campo
- 0Spanish Network for Research in Infectious Diseases – Red Española de Investigación en Patología InfecciosaSevilla, Spain
- Tim Waterboer
- Division of Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ)Heidelberg, Germany
- Nuria Aragonés
- Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Instituto de Salud Carlos IIIMadrid, Spain
- Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER of Epidemiology and Public Health) – Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)Madrid, Spain
- DOI
- https://doi.org/10.3389/fmicb.2017.00888
- Journal volume & issue
-
Vol. 8
Abstract
Background: Several studies have suggested that Helicobacter pylori (H. pylori) infection is a risk factor for colorectal cancer (CRC), while others have not confirmed this hypothesis. This work aimed to assess the relation of CRC with H. pylori seropositivity and with seropositivity to 16 H. pylori proteins, in the MultiCase-Control study, MCC-Spain.Methods: MCC-Spain is a multicase-control study carried out in Spain from 2008 to 2013. In total, 2,140 histologically-confirmed incident CRC cases and 4,098 population-based controls were recruited. Controls were frequency-matched by sex, age, and province. Epidemiological data were collected through a questionnaire fulfilled by face-to-face interviews and a self-administered food-frequency questionnaire. Seroreactivities against 16 H. pylori proteins were determined in 1,488 cases and 2,495 controls using H. pylori multiplex serology. H. pylori seropositivity was defined as positivity to ≥4 proteins. Multivariable logistic regression mixed models were used to estimate odds ratios (OR) and 95% confidence intervals (CI).Results:H. pylori seropositivity was not associated with increased CRC risk (OR = 0.91; 95% CI: 0.71–1.16). Among H. pylori seropositive subjects, seropositivity to Cagδ showed a lower CRC risk, and risk decreased with increasing number of proteins seropositive. Seropositivity to the most recognized virulence factors, CagA and VacA, was not associated with a higher CRC risk. No statistically significant heterogeneity was identified among tumor sites, although inverse relations were stronger for left colon cancer. An interaction with age and sex was found: H. pylori seropositivity was associated with a lower CRC risk in men younger than 65 and with a higher risk in older women.Conclusions: Our results suggest that neither H. pylori seropositivity, nor seropositivity to the virulence factor CagA are associated with a higher CRC risk. A possible effect modification by age and sex was identified.
Keywords
- Helicobacter pylori
- multiplex serology
- colorectal neoplasm
- chronic infection
- bacterial infections
- non-infectious diseases